Aesica to increase presence in Asia

Aesica Pharmaceuticals has announced the promotion of Joe Zou currently Chief Representative of its Shanghai office, to manage regional sales across Asia, particularly in China.

Joe has worked for Aesica since 2008, based in the company’s Shanghai office and prior to this he worked for Whytes Chemicals Ltd. as Manager of its China office for nine years.

Joe’s new position will contribute to Aesica’s strategy to become the number one supplier of Active Pharmaceutical Ingredients (APIs) and Formulated Products, as developing business streams across Asia will significantly enhance the company’s portfolio. Joe will work closely with the team at the Head Office in the United Kingdom, to increase Aesica’s presence in Asia, particularly in China, which, as a BRIC country (Brazil, Russia, India, China) has one of the fastest growing economies in the world and further expansion into this market is a natural progression for Aesica.

Joe said of his new appointment: “Aesica has had a presence in China for some time now and my new position within the company brings the responsibility of increasing sales outputs, not only in China, but across the whole of Asia. It is a large region to manage with huge potential, however, having worked in Shanghai for over twelve years I have many strong established contacts and I’m looking forward to the prospect of developing business further here in Asia.”

Dr Alan Raymond, Sales & Marketing Director, Aesica, said: “We have made no secret of the fact that we wish to expand into Asia and this strategic promotion for Joe Zou will help us to achieve a greater presence in China and beyond. Joe has worked in China for many years, speaks the language, knows the culture and has very strong relationships with a number of contacts across the region. Joe is in a position to forge important relationships for Aesica.”

Aesica is a leading full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.

Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within Aesica enables it to provide primary and secondary contract manufacturing services to the highest possible regulatory standards. It is this full-service offer, its dedication to exceptional standards of service and its ability to deliver innovation and added value for its clients that truly sets Aesica apart from its counterparts.

For more information about Aesica please visit www.aesica-pharma.com